# Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Study · id `cardio:ct-nct07271186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07271186](<https://clinicaltrials.gov/study/NCT07271186>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07271186

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.

## Technical summary

Registry record NCT07271186. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-09 (actual); primary completion 2028-10-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 195 participants (planned count; ClinicalTrials.gov record NCT07271186, source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)
- Started: 2026-01-09 (actual) (ClinicalTrials.gov record NCT07271186, source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2028-10-13 (anticipated) (ClinicalTrials.gov record NCT07271186, source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)
- Completion: 2028-10-13 (anticipated) (ClinicalTrials.gov record NCT07271186, source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07271186, source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07271186-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- Acronym: ANCHOR-POC
- Condition: Diabetic Kidney Disease (DKD)
- Intervention (Drug): ALN-ANG3
- Intervention (Drug): Evinacumab
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 89f5b38bab61875aa49af5b9ad916ca53e0cd3a5be9da8e498010386c292bbda
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
